Novelion Therapeutics Stock Price, News & Analysis (NASDAQ:NVLN)

$4.09 0.22 (5.68 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$4.09
Today's Range$3.82 - $4.09
52-Week Range$3.08 - $12.12
Volume25,604 shs
Average Volume48,536 shs
Market Capitalization$76.29 million
P/E Ratio-0.59
Dividend YieldN/A
Beta0.57

About Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics logoNovelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:NVLN
CUSIPN/A
Phone604-707-7000

Debt

Debt-to-Equity Ratio6.53%
Current Ratio1.45%
Quick Ratio1.28%

Price-To-Earnings

Trailing P/E Ratio-0.585120765206344
Forward P/E Ratio-0.46
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.57 million
Price / Sales5.62
Cash FlowN/A
Price / CashN/A
Book Value$7.33 per share
Price / Book0.56

Profitability

Trailing EPS($6.99)
Net Income$-52,870,000.00
Net Margins-173.51%
Return on Equity-318.34%
Return on Assets-47.02%

Miscellaneous

Employees163
Outstanding Shares18,650,000

Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc (NASDAQ:NVLN) issued its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by $0.60. Novelion Therapeutics had a negative net margin of 173.51% and a negative return on equity of 318.34%. View Novelion Therapeutics' Earnings History.

When will Novelion Therapeutics make its next earnings announcement?

Novelion Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for Novelion Therapeutics.

Where is Novelion Therapeutics' stock going? Where will Novelion Therapeutics' stock price be in 2018?

2 equities research analysts have issued 12-month target prices for Novelion Therapeutics' shares. Their predictions range from $8.00 to $8.00. On average, they expect Novelion Therapeutics' share price to reach $8.00 in the next year. View Analyst Ratings for Novelion Therapeutics.

Are investors shorting Novelion Therapeutics?

Novelion Therapeutics saw a increase in short interest in the month of December. As of December 15th, there was short interest totalling 2,004,139 shares, an increase of 58.5% from the November 30th total of 1,264,392 shares. Based on an average daily trading volume, of 159,535 shares, the days-to-cover ratio is currently 12.6 days. Approximately 12.0% of the shares of the stock are sold short.

Who are some of Novelion Therapeutics' key competitors?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the folowing people:

  • Jason M. Aryeh, Independent Chairman of the Board
  • Michael Dennis Price, Chief Financial Officer, Senior Vice President
  • Jeffrey S. Hackman, Chief Operating Officer, Executive Vice President
  • Barbara Y. Chan, Chief Accounting Officer
  • Suzanne Louise Bruhn Ph.D., Director
  • Mark H.N. Corrigan M.D., Director
  • Mark A. DiPaolo, Director
  • , Bio & Compensation - 
  • Kevin Kotler, Director
  • , Bio & Compensation - 
  • John J. Orloff M.D., Director

How do I buy Novelion Therapeutics stock?

Shares of Novelion Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of Novelion Therapeutics stock can currently be purchased for approximately $4.09.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $76.29 million and generates $13.57 million in revenue each year. The biotechnology company earns $-52,870,000.00 in net income (profit) each year or ($6.99) on an earnings per share basis. Novelion Therapeutics employs 163 workers across the globe.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 887 GREAT NORTHERN WAY SUITE 250, VANCOUVER A1, V5T 4T5. The biotechnology company can be reached via phone at 604-707-7000 or via email at [email protected]


MarketBeat Community Rating for Novelion Therapeutics (NVLN)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  213
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novelion Therapeutics (NASDAQ:NVLN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$8.00$9.00$10.00
Price Target Upside: 81.41% upside81.41% upside25.70% upside0.40% downside

Novelion Therapeutics (NASDAQ:NVLN) Consensus Price Target History

Price Target History for Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics (NASDAQ:NVLN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Royal Bank of CanadaLower Price TargetSector Perform$9.00 -> $8.00N/AView Rating Details
6/19/2017Bloom BurtonReiterated RatingAccumulateLowView Rating Details
(Data available from 1/21/2016 forward)

Earnings

Novelion Therapeutics (NASDAQ:NVLN) Earnings History and Estimates Chart

Earnings by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics (NASDAQ NVLN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018        
11/9/2017Q3 2017($0.29)($0.89)ViewN/AView Earnings Details
8/8/20176/30/2017($0.09)($0.13)$36.86 million$40.90 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.47)($0.54)ViewN/AView Earnings Details
3/15/201712/31/2016($0.50)($1.76)$40.10 million$13.57 millionViewN/AView Earnings Details
11/1/2016Q316($0.12)($0.11)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.45)($0.50)ViewN/AView Earnings Details
5/5/2016Q116($0.09)($0.41)ViewN/AView Earnings Details
2/25/2016Q415($0.09)($0.06)ViewN/AView Earnings Details
10/29/2015Q3($0.10)($0.05)ViewN/AView Earnings Details
7/30/2015Q2($0.09)($0.21)ViewN/AView Earnings Details
4/30/2015Q115($0.06)($0.12)ViewN/AView Earnings Details
2/26/2015Q414($0.09)($0.05)ViewN/AView Earnings Details
10/28/2014Q314($0.12)($0.10)ViewN/AView Earnings Details
8/5/2014Q214($0.12)($0.17)ViewN/AView Earnings Details
4/30/2014Q114($0.11)($0.13)ViewN/AView Earnings Details
2/28/2014Q413($0.14)($0.10)ViewN/AView Earnings Details
11/7/2013Q313($0.11)($0.15)ViewN/AView Earnings Details
8/1/2013Q213($0.10)($0.12)ViewN/AView Earnings Details
5/2/2013Q113($0.14)($0.13)ViewN/AView Earnings Details
2/21/2013Q412($0.22)($0.18)ViewN/AView Earnings Details
11/7/2012Q312($0.22)($0.25)$9.60 millionViewN/AView Earnings Details
8/2/2012($0.23)($0.33)ViewN/AView Earnings Details
5/3/2012($0.20)($0.21)ViewN/AView Earnings Details
2/23/2012($0.20)$0.04ViewN/AView Earnings Details
11/3/2011Q3 2011($0.85)($0.07)ViewN/AView Earnings Details
7/28/2011($0.13)($0.12)ViewN/AView Earnings Details
5/5/2011($0.15)($0.17)ViewN/AView Earnings Details
3/1/2011Q4 2010($0.65)$0.25ViewN/AView Earnings Details
11/3/2010Q3 2010($0.35)($0.07)ViewN/AView Earnings Details
7/27/2010Q2 2010($0.20)$0.55ViewN/AView Earnings Details
5/6/2010Q1 2010($0.45)($0.39)ViewN/AView Earnings Details
3/10/2010Q4 2009($0.10)($0.49)ViewN/AView Earnings Details
10/27/2009Q3 2009$0.20$0.23ViewN/AView Earnings Details
7/28/2009Q2 2009$0.20$0.40ViewN/AView Earnings Details
4/28/2009Q1 2009$0.10$0.10ViewN/AView Earnings Details
2/19/2009Q4 2008($0.15)$0.31ViewN/AView Earnings Details
10/28/2008Q3 2008($0.70)$0.20ViewN/AView Earnings Details
7/29/2008Q2 2008($0.20)($0.28)ViewN/AView Earnings Details
4/25/2008Q1 2008($0.18)ViewN/AView Earnings Details
2/21/2008Q4 2007($0.20)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Novelion Therapeutics (NASDAQ:NVLN) Earnings Estimates

Current Year EPS Consensus Estimate: $-8.95 EPS
Next Year EPS Consensus Estimate: $-5.67 EPS

Dividends

Novelion Therapeutics (NASDAQ:NVLN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/18/2013special$3.926/28/20136/24/20136/27/2013
(Data available from 1/1/2013 forward)

Insider Trades

Novelion Therapeutics (NASDAQ NVLN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.10%
Institutional Ownership Percentage: 75.55%
Insider Trades by Quarter for Novelion Therapeutics (NASDAQ:NVLN)
Institutional Ownership by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics (NASDAQ NVLN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/12/2017Donald K SternDirectorBuy2,500$9.10$22,750.002,500View SEC Filing  
5/15/2017Jason AryehDirectorBuy361$8.95$3,230.95View SEC Filing  
9/15/2016Stonepine Capital, L.P.Major ShareholderBuy133,496$1.55$206,918.80View SEC Filing  
12/29/2015Jason AryehDirectorBuy18,400$2.50$46,000.0074,000View SEC Filing  
6/16/2015Axial Capital Master, L.P.Major ShareholderSell7,563,053$3.47$26,243,793.91View SEC Filing  
6/16/2015Jason AryehDirectorBuy288,000$3.47$999,360.00View SEC Filing  
12/22/2014John W KozarichDirectorBuy10,000$3.59$35,900.00View SEC Filing  
12/18/2014Jeffrey A MecklerDirectorBuy20,000$3.60$72,000.00View SEC Filing  
7/11/2014Public Equity K/S NbMajor ShareholderSell1,000,000$5.80$5,800,000.00View SEC Filing  
7/1/2013Axial Capital Master, L.P.Major ShareholderSell288,890$4.39$1,268,227.10View SEC Filing  
6/28/2013Jeffrey A MecklerDirectorBuy30,000$4.36$130,800.00View SEC Filing  
5/14/2013Sukhi JagpalCFOSell10,000$7.95$79,500.00View SEC Filing  
5/13/2013John W KozarichDirectorBuy10,000$7.97$79,700.00View SEC Filing  
5/3/2013Jeffrey A MecklerDirectorBuy20,000$7.96$159,200.00View SEC Filing  
12/28/2012Alexander R LussowVPSell230,000$7.52$1,729,600.00View SEC Filing  
10/5/2012Alexander R LussowVPSell5,000$7.72$38,600.00View SEC Filing  
9/5/2012Alexander R LussowVPSell5,000$7.55$37,750.00View SEC Filing  
8/8/2012Linda LupiniVPSell22,993$7.85$180,495.05View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novelion Therapeutics (NASDAQ NVLN) News Headlines

Source:
DateHeadline
Novelion Therapeutics (NVLN) Stock Rating Lowered by Zacks Investment ResearchNovelion Therapeutics (NVLN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 17 at 9:18 AM
How Should You Think About Novelion Therapeutics Inc’s (NASDAQ:NVLN) Risks?How Should You Think About Novelion Therapeutics Inc’s (NASDAQ:NVLN) Risks?
finance.yahoo.com - January 10 at 4:38 PM
Novelion Therapeutics Inc (NVLN) Short Interest Up 58.5% in DecemberNovelion Therapeutics Inc (NVLN) Short Interest Up 58.5% in December
www.americanbankingnews.com - December 31 at 4:22 AM
Aegerion says judge’s rejection of $40M plea clouds futureAegerion says judge’s rejection of $40M plea clouds future
finance.yahoo.com - December 22 at 7:36 PM
Contrasting Novelion Therapeutics (NVLN) and The CompetitionContrasting Novelion Therapeutics (NVLN) and The Competition
www.americanbankingnews.com - December 18 at 7:22 PM
Is Novelion Therapeutics Inc (NASDAQ:NVLN) Cheap And High Growth?Is Novelion Therapeutics Inc (NASDAQ:NVLN) Cheap And High Growth?
finance.yahoo.com - December 15 at 4:55 PM
Critical Review: Novelion Therapeutics (NVLN) and Its CompetitorsCritical Review: Novelion Therapeutics (NVLN) and Its Competitors
www.americanbankingnews.com - December 15 at 1:30 AM
Novelion Therapeutics (NVLN) vs. Its Rivals Head-To-Head SurveyNovelion Therapeutics (NVLN) vs. Its Rivals Head-To-Head Survey
www.americanbankingnews.com - December 14 at 9:26 PM
Financial Analysis: Novelion Therapeutics (NVLN) and Its RivalsFinancial Analysis: Novelion Therapeutics (NVLN) and Its Rivals
www.americanbankingnews.com - December 14 at 1:30 PM
Novelion Therapeutics (NVLN) Names Michael Price as SVP and CFONovelion Therapeutics (NVLN) Names Michael Price as SVP and CFO
www.streetinsider.com - December 4 at 10:15 AM
What Investors Should Know About Novelion Therapeutics Inc’s (NVLN) Financial StrengthWhat Investors Should Know About Novelion Therapeutics Inc’s (NVLN) Financial Strength
finance.yahoo.com - November 27 at 4:43 PM
Zacks Investment Research Downgrades Novelion Therapeutics Inc. (NVLN) to SellZacks Investment Research Downgrades Novelion Therapeutics Inc. (NVLN) to Sell
www.americanbankingnews.com - November 18 at 6:16 PM
Novelion Therapeutics Inc. (NVLN) Short Interest Up 34.9% in OctoberNovelion Therapeutics Inc. (NVLN) Short Interest Up 34.9% in October
www.americanbankingnews.com - November 13 at 2:32 AM
Novelion Therapeutics reports 3Q lossNovelion Therapeutics reports 3Q loss
finance.yahoo.com - November 12 at 11:08 AM
Should You Buy Novelion Therapeutics Inc (NVLN)?Should You Buy Novelion Therapeutics Inc (NVLN)?
finance.yahoo.com - November 12 at 11:08 AM
Novelion Therapeutics Inc. (NVLN) PT Lowered to $8.00 at Royal Bank Of CanadaNovelion Therapeutics Inc. (NVLN) PT Lowered to $8.00 at Royal Bank Of Canada
www.americanbankingnews.com - November 10 at 3:10 PM
U.S. submits revised plea deal with Novelions Aegerion to courtU.S. submits revised plea deal with Novelion's Aegerion to court
finance.yahoo.com - November 2 at 7:05 AM
U.S. judge says he may reject plea deal with Novelions AegerionU.S. judge says he may reject plea deal with Novelion's Aegerion
finance.yahoo.com - October 19 at 6:59 AM
Zacks: Brokerages Expect Novelion Therapeutics Inc. (NVLN) Will Post Earnings of -$0.29 Per ShareZacks: Brokerages Expect Novelion Therapeutics Inc. (NVLN) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - October 10 at 2:08 AM
Patient assistance charity says U.S. contacted it in probePatient assistance charity says U.S. contacted it in probe
finance.yahoo.com - October 2 at 7:19 PM
Corporate News Blog - Novelions Subsidiary Aegerion Pleads Guilty for Misbranding Juxtapid; Agrees to a Settlement of $40 MillionCorporate News Blog - Novelion's Subsidiary Aegerion Pleads Guilty for Misbranding Juxtapid; Agrees to a Settlement of $40 Million
finance.yahoo.com - October 2 at 7:19 PM
SEC fines pharmaceutical company $4.1 million for misleading performance metricSEC fines pharmaceutical company $4.1 million for misleading performance metric
finance.yahoo.com - September 23 at 8:55 AM
Aegerion finalizes $40M settlement, guilty plea in drug misbranding caseAegerion finalizes $40M settlement, guilty plea in drug misbranding case
finance.yahoo.com - September 23 at 8:55 AM
Novelions Aegerion resolves U.S. drug probes for $40 mlnNovelion's Aegerion resolves U.S. drug probes for $40 mln
finance.yahoo.com - September 23 at 8:55 AM
 Analysts Anticipate Novelion Therapeutics Inc. (NVLN) Will Post Earnings of -$0.29 Per Share Analysts Anticipate Novelion Therapeutics Inc. (NVLN) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - September 21 at 2:26 PM
Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of DirectorsNovelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors
feeds.benzinga.com - September 11 at 9:23 AM
-$0.29 EPS Expected for Novelion Therapeutics Inc. (NVLN) This Quarter-$0.29 EPS Expected for Novelion Therapeutics Inc. (NVLN) This Quarter
www.americanbankingnews.com - August 15 at 12:22 PM
Novelion Therapeutics Reports Second Quarter 2017 Financial ResultsNovelion Therapeutics Reports Second Quarter 2017 Financial Results
globenewswire.com - August 9 at 5:41 AM
Novelion Therapeutics Reports Second Quarter 2017 Financial ResultsNovelion Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 5:41 AM
Novelion Therapeutics reports 2Q lossNovelion Therapeutics reports 2Q loss
finance.yahoo.com - August 9 at 5:41 AM
Novelion Therapeutics Inc. (NASDAQ:NVLN) Posts  Earnings Results, Beats Estimates By $0.01 EPSNovelion Therapeutics Inc. (NASDAQ:NVLN) Posts Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 8 at 2:40 PM
Novelion Therapeutics Inc. (NVLN) Set to Announce Earnings on TuesdayNovelion Therapeutics Inc. (NVLN) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - August 3 at 11:27 AM
Novelion Therapeutics Appoints Mark DiPaolo to Board of DirectorsNovelion Therapeutics Appoints Mark DiPaolo to Board of Directors
finance.yahoo.com - August 3 at 6:27 AM
Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - July 29 at 5:45 AM
Novelion Therapeutics Inc. (NASDAQ:NVLN) Short Interest Up 78.7% in JuneNovelion Therapeutics Inc. (NASDAQ:NVLN) Short Interest Up 78.7% in June
www.americanbankingnews.com - July 16 at 7:22 AM
Novelion Therapeutics (NVLN) Announces Presentation of Metreleptin Data at ADANovelion Therapeutics (NVLN) Announces Presentation of Metreleptin Data at ADA
www.streetinsider.com - June 14 at 12:05 AM
Novelion Therapeutics (NVLN) Granted Request to Voluntarily Delist from Toronto Stock ExchangeNovelion Therapeutics (NVLN) Granted Request to Voluntarily Delist from Toronto Stock Exchange
www.streetinsider.com - April 19 at 11:59 PM
Novelion Therapeutics (NVLN) Appoints Mark Corrigan to Board of DirectorsNovelion Therapeutics (NVLN) Appoints Mark Corrigan to Board of Directors
www.streetinsider.com - April 2 at 10:46 AM
NOVELION THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExNOVELION THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
biz.yahoo.com - March 31 at 9:06 AM
Novelion Therapeutics (NVLN) to Present New Data on MYALEPT® (metreleptin) at Endocrine Society, 4/1 -4/4Novelion Therapeutics (NVLN) to Present New Data on MYALEPT® (metreleptin) at Endocrine Society, 4/1 -4/4
www.streetinsider.com - March 31 at 12:15 AM
Novelion Therapeutics’ Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine SocietyNovelion Therapeutics’ Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
us.rd.yahoo.com - March 30 at 7:14 PM
NOVELION THERAPEUTICS INC. Files SEC form 10-K, Annual ReportNOVELION THERAPEUTICS INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 30 at 7:14 PM
Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial ResultsNovelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results
us.rd.yahoo.com - March 15 at 9:46 AM
NOVELION THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors orNOVELION THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or
us.rd.yahoo.com - March 15 at 9:46 AM
Novelion Therapeutics to Announce Preliminary Fourth Quarter and Full Year 2016 Financial Results on March ...Novelion Therapeutics to Announce Preliminary Fourth Quarter and Full Year 2016 Financial Results on March ...
globenewswire.com - March 13 at 6:38 PM
Novelion Therapeutics Announces Presentation at the 29th Annual ROTH Conference - GlobeNewswire (press release)Novelion Therapeutics Announces Presentation at the 29th Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 8 at 7:43 PM
U.S. Patent Trial and Appeal Board Affirms Lomitapide Patents with Favorable IPR DecisionsU.S. Patent Trial and Appeal Board Affirms Lomitapide Patents with Favorable IPR Decisions
us.rd.yahoo.com - March 7 at 10:01 AM
Novelion Therapeutics (NVLN) Noses Forward on Rare Disease DayNovelion Therapeutics (NVLN) Noses Forward on Rare Disease Day
www.msn.com - February 28 at 10:37 AM
Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines AgencyNovelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency
us.rd.yahoo.com - January 23 at 9:47 AM
Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 OutlookNovelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook
us.rd.yahoo.com - January 10 at 12:40 AM

SEC Filings

Novelion Therapeutics (NASDAQ:NVLN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novelion Therapeutics (NASDAQ:NVLN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novelion Therapeutics (NASDAQ NVLN) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.